
Protalix BioTherapeutics, Inc.: updates and filings
Price
$2.88
November 17, 2026Market cap $232M
What Ploutos Investor adds for Protalix BioTherapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 10, 2026next Feb 12, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
May 2026
March 2026
January 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 10, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 10, 2026Results of operationsForm8-K
- Oct 15, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 12, 2026Shares registered for employeesFormS-8
- Aug 12, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 12, 2026Results of operationsForm8-K
- Jul 29, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jun 25, 2026Shareholder voteForm8-K
- May 21, 2026Regulation FD disclosureForm8-K
- May 13, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 13, 2026Results of operationsForm8-K
- Apr 30, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 30, 2026Annual meeting proxy statementFormDEF 14A
- Mar 30, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 18, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Mar 18, 2026Results of operationsForm8-K
- Mar 9, 2026Other material eventsForm8-K
- Mar 4, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Feb 11, 2026Regulation FD disclosureForm8-K
- Jan 30, 2026Other material eventsForm8-K
- Jan 5, 2026Regulation FD disclosureForm8-K
- Nov 13, 2025Quarterly reportfor the period to Sep 30, 2025Form10-Q
- Nov 13, 2025Results of operationsForm8-K
- Nov 3, 2025Other material eventsForm8-K
- Oct 17, 2025Regulation FD disclosure, other material eventsForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 10, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 10, 2026 | 8-K | Results of operations | Document |
| Oct 15, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 12, 2026 | S-8 | Shares registered for employees | Document |
| Aug 12, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 12, 2026 | 8-K | Results of operations | Document |
| Jul 29, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jun 25, 2026 | 8-K | Shareholder vote | Document |
| May 21, 2026 | 8-K | Regulation FD disclosure | Document |
| May 13, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 13, 2026 | 8-K | Results of operations | Document |
| Apr 30, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 30, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 30, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 18, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Mar 18, 2026 | 8-K | Results of operations | Document |
| Mar 9, 2026 | 8-K | Other material events | Document |
| Mar 4, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Feb 11, 2026 | 8-K | Regulation FD disclosure | Document |
| Jan 30, 2026 | 8-K | Other material events | Document |
| Jan 5, 2026 | 8-K | Regulation FD disclosure | Document |
| Nov 13, 2025 | 10-Q | Quarterly reportfor the period to Sep 30, 2025 | Document |
| Nov 13, 2025 | 8-K | Results of operations | Document |
| Nov 3, 2025 | 8-K | Other material events | Document |
| Oct 17, 2025 | 8-K | Regulation FD disclosure, other material events | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Aug 13, 1996.
The full analysis
What do Protalix BioTherapeutics's filings show?
The filings are where every one of Protalix BioTherapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.